Selank

Selank Nasal Spray is supplied by PeptaGen Labs as a catalogued research material in the following format and strength: nasal spray, 10mg/10ml. This catalogue presentation identifies the supplied formulation; it does not establish equivalence to materials described in published research.

Selank is a defined seven-residue, tuftsin-derived peptide with the sequence H-TKPRPGP-OH. The free peptide, N-acetyl analogue, and acetate or TFA materials are distinct analytical articles. Sequence, termini and counter-ion must therefore match the batch identity record rather than being inferred from the Selank name alone.

Chemical properties and registry information

Formula, molecular mass and registry identifiers describe the specified peptide entity, not the complete spray formulation. Their applicability depends on the sequence, termini and material form documented for the batch.

Research background and published evidence

Published research

Published Selank research includes peptide identity and degradation studies, alongside cellular and animal-model investigations of gene expression. Exploratory work has examined GABA-related pathways, including transcriptomic research in a rodent model. These publications provide context for mechanistic investigation but do not characterise this catalogue spray or establish its formulation-specific properties.

Current scientific understanding

A single validated direct receptor target has not been established. The literature is predominantly mechanistic, cellular and animal-model research and does not establish a human-use profile for this product. Findings require interpretation against the exact experimental material, model, analytical method and study conditions. Results involving N-acetyl Selank, other salts or separately manufactured products are not interchangeable with evidence for this batch.

Formulation note

The published research base primarily concerns materials or experimental routes other than this specific nasal spray formulation. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Peptide identity alone does not demonstrate equivalence across excipient systems, containers or material forms. Any assessment of formulation composition, degradation or analytical behaviour requires evidence specific to the supplied presentation.

Quality and testing

Quality documentation must be linked to the exact product, presentation and lot. Consult the batch-specific CoA for reported identity, content, analytical methods and results, and the SDS for documented composition and material information. A report for another lot, strength or similarly named peptide is not evidence for this product.

Chromatographic area purity, peptide identity, analyte content, counter-ion content, sterility, endotoxin and elemental impurities are separate measurements. One result does not establish the others. Only tests supported by an available, matching batch report should be regarded as documented; the catalogue strength and spray format do not independently verify those attributes.

Supplied exclusively for laboratory research by qualified professionals. Not for human or veterinary use. No dosing or administration directions are provided.